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Ebola virus disease (EVD) is a haemorrhagic fever caused by Ebola 
virus (EBOV) with high infectivity and mortality [1]. EBOV is an 
enveloped, single-stranded, and negative-sense RNA virus belonging 
to the Filoviridae family [2]. In contrast to the genus Marburg virus 
which contains one single species, the genus Ebola virus contains 5 
species: Zaire Ebola virus (ZEBOV), Sudan Ebola virus (SUDV), Taï 
Forest Ebola virus (TAFV), Bundibugyo Ebola virus (BDBV) which are 
pathogenic for humans, and Reston Ebola virus (RESTV) which infects 
non-human primates [3]. 
EBOV was first discovered in 1976 in the Democratic Republic of 
Congo (DRC) and simultaneously in Sudan [4,5]. Since 1976, EVD has 
appeared sporadically in DRC, Sudan, Gabon, Uganda, and Congo, 
with small to large outbreaks and lethality ranging from 50 to 100% 
[6,7] with about 2500 cumulative cases until 2013 [8].
Several studies suggest that EBOV is transmitted to humans 
from animals, and fruit bats are considered as probable reservoir 
[9,10]. Humans are infected through close contact with the organs, 
blood, and other biological fluids of infected animals and human-to-
human transmission can occur through blood, body fluids or mucosal 
exposures [11,12]. The virus has been found in the blood, saliva, feces, 
breast milk, tears, and genital secretions of infected patients [8]. After 
an incubation period of 2-21 days, symptoms appear suddenly with 
fever, asthenia, headaches, myalgia, vomiting, diarrhea and bleeding 
in severe cases. 
Treatment is largely through supportive care, such as rehydration 
and treatment of symptoms. Currently, several prophylactic or 
therapeutic strategies are being evaluated but none have been approved 
[13-16]. A Multi-factorial approach is therefore needed for EVD control, 
with laboratory surveillance and epidemiological investigation playing 
crucial roles in case confirmation and contact tracing. EVD diagnosis 
can be done only in specific laboratories and different tests to confirm 
EVD include antibody-capture enzyme-linked immunosorbent assay 
(ELISA) for antigen detection,, reverse transcriptase polymerase chain 
reaction (RT-PCR), real time RT-PCR assay for RNA detection and 
virus isolation by cell culture [17] and IgM/IgG detection for cases 
that have progressed beyond the diagnostic window for direct virus 
detection assays.
In March 2014 the WHO was notified of an EVD outbreak in 
Guinea caused by ZEBOV [18], which subsequently spread into 
other West African countries and developed into the largest outbreak 
recorded since the discovery of the virus.
The 2014 Ebola virus outbreak
An EVD outbreak started in December 2013 in Guéckédou, in the 
southeastern region of Guinea but was only identified and notified 
to the WHO in March 2014 due to a lack of diagnostic capacity and 
resources [18,19]. The first samples were sent to Institut Pasteur Lyon, 
France by MSF conducting an investigation in Guinea on behalf of the 
WHO. EBOV was confirmed in samples from infected patients and 
on March 23rd, 2014 the WHO publicly announced the outbreak in 
Guinea [19]. The first detection of the EVD on site in Guinea was done 
by the Institut Pasteur de Dakar deployment team on 23 March 2014 
in Conakry. 
The origin of the disease in West Africa rather than in central 
Africa, the delay in identification and the expansion into urban areas 
and neighbour countries (Liberia, Sierra Leone, Nigeria, Senegal 
and Mali) were particular features of this outbreak. WHO declared 
the outbreak a public health emergency of international concern on 
August 8th 2014 [19,20]. Up to January 31st 2016, 28 639 confirmed, 
probable and suspected Ebola cases and 11 316 deaths were reported 
[21]. In Guinea, Liberia and Sierra Leone a total of 3 804, 10 675, 14 
124 confirmed cases, resulted in 2 536, 4 809, 3 956 deaths respectively 
(case-fatality rates 66.66%, 45.04%, 28.00%).
In the countries less affected, Nigeria, Mali, and Senegal, 20, 8, and 
1 confirmed cases were reported, including, 8, 6, and 0 deaths. Case-
fatality rates for these countries were 40%, 75%, and 0%, respectively 
[22]. Senegal was the fifth West African country to be affected but 
managed a rapid response due to the early alert given by public health 
staff in Guinea from where the index case was arriving [23]. 
In addition to West African countries, confirmed cases were 
reported in Spain, Italy, United Kingdom (1 case and 0 death for each 
country), and United States of America (4 cases and 1 death). Therefore 
this outbreak affected 10 countries in 3 different continents and this 
highlights how a disease known to be restricted to Africa can spread to 
many countries in the world through international travel.
The EVD outbreak in Liberia was declared over on 9 May 2015 
[24]. However, the routine surveillance detected 6 new EVD cases 
Faye O (2016) Workshop on mobile laboratories deployed in the Ebola outbreak in West-Africa 2014-2015
Clin Microbiol Infect Dis, 2016         doi: 10.15761/CMID.1000S1001  Volume 1(4): 2-3
from 29 June to 12 July and 3 in November 2015 [25,26]. Preliminary 
evidence from genomic sequencing strongly suggested that the most 
likely origin of transmissions was a re-emergence of the virus from 
survivors within Liberia [25,27]. Finally, the outbreak was declared 
over on 14 January 2016 [28]. 
In Guinea, the outbreak was declared over on 29 December 
2015 [27]. In Sierra Leone, the outbreak was declared to have ended 
on 7 November 2015 and the country entered a 90-day period of 
enhanced surveillance. However, on 14 January, 68 days into the 90-
day surveillance period, a new confirmed case of EVD was reported in 
Sierra Leone. Among the close contacts, one was tested also positive for 
Ebola virus on 20 January 2016 and the contacts of this last case were 
followed until February 11th.
Taken together, the situations in Liberia and Sierra Leone suggest 
that surveillance measures are essential to ensure the rapid detection of 
any reintroduction or re-emergence of EVD.
First EVD cases were reported from and the disease was limited to 
the Gueckedou, Guinean forests region until March 21st 2014. Due to 
the lack of appropriate health facilities in rural Africa, patients often 
visit capitals for better care. This led to the first case of Ebola recorded 
in a Conakry hospital on March 26th and chains of transmission of the 
disease in the capital were initiated through health care workers. Two 
major phases were observed during the Ebola epidemic in Guinea. The 
first phase covered the period March-July 2014 during which health 
personnel contributed considerably to the transmission of the virus 
[29]. This situation could be explained by several factors: Ebola was 
unknown in the region, its confusion with infectious diseases endemic 
in the region (malaria, etc.) and the lack of appropriate structures and 
equipment to manage patients.
During the second phase of the Ebola epidemic in Guinea, the most 
intense and longest phase, which began in August 2014 following the 
introduction of the virus via Sierra Leonne, funeral rites contributed to 
the spread of the disease in the country, as community members often 
touch and wash the body of the deceased, thus inadvertently initiating 
chains of transmissions. 
In April 2015 a reinforced Ebola virus disease surveillance 
strategy with the aim of reaching the “zero case” goal set by the Ebola 
Emergency committee in Guinea was launched. For this purpose, all 
of the deceased in districts of Conakry most recently affected by the 
Ebola virus outbreak had to be tested. The field deployment of a mobile 
suitcase laboratory using RPA which provided results in 30-40 minutes 
helped to improve burial management and community engagement in 
the Matoto district in Conakry [30].
It is important to note that before 2014, Ebola epidemics were 
confined to rural areas. However, during the West Africa Ebola 
outbreak in 2014, large cities were affected including Conakry, Guinea’s 
capital (population 2 million). Tracing the virus particularly contact 
follow-up in the 4 municipalities of Conakry in highly populated urban 
areas, were difficult and social reticence often reported. Local and 
international health personnel were often blamed to introduce Ebola 
virus responsible for the disease and the dead. 
During the outbreak up to 24 organizations operated laboratories at 
40 sites in Guinea, Sierra Leone and Liberia. In March 2016 representatives 
of ten organisations which had deployed (mobile) laboratories to 16 sites 
across the three countries in West-Africa (Table 1) convened for a two 
day symposium in Dakar (4-5.02.16) to exchange their experiences. The 
meeting was organized by the Ebola MODRAD consortium. 
The meeting was also attended by representatives of Medicines sans 
frontiers and African colleagues of the Laboratoire de Bacteriologie 
Virologie, Universite Cheikh Anta DIOP, Dakar, Sengal, the Laboratoire 
de Bactériologie-Virologie, CHNU Aristide Le Dantec Dakar, Sengal 
the MRC West Africa Collaboration, Medical Research Council 
Unit, Gambia and the Institut National de Recherche Biomédicale, 
Kinshasa, DRC. 
This special issue reports experiences made during the deployment 
and summarizes the discussion during the meeting which hopefully 
will help to optimize future deployments of this kind. This meeting did 
not assemble all organisations actively deploying mobile laboratories 
in the EVD outbreak in West Africa nor did all organisations choose to 
publish their experiences in this special issue. Additional publications 
on mobile laboratory deployments have been published in other 
journals [31-39]. 
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